- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05483426
Prevalence of Sexual Addiction in an Inmate Population at the Muret Detention Center in Haute-Garonne (PAS-CD) (PAS-CD)
Prevalence of Sexual Addiction in an Inmate Population at the Muret Detention Center in Haute-Garonne.
Sexual addiction, also known as hypersexuality or compulsive sexuality, is a human sexual behavior that results in a continuous and persistent search for sexual pleasure. Replacing the former terms satyriasis and nymphomania, the World Health Organization (WHO) ICD-11 has referred to this disorder as "compulsive sexual behavior disorders".
From multiple causes (iatrogeny, neurological causes, psychiatric causes, psychopathological hypotheses), but still only partially known, the inclusion of this disorder among impulsivity-related disorders, obsessive-compulsive disorders or addiction-related disorders is still debated in the scientific literature. Thus, in the absence of sufficient robust scientific data, DSM-5 refused to include this disorder in its classification.
However, the consequences of this disorder on the psychosocial functioning of individuals are not negligible, which can go as far as the precipitation of a transition to an heteroaggressive act which can thus lead to incarceration.
The prevalence of this disorder in the general population is estimated between 2 and 6% based on current literature data. This rate appears to be higher among men and more specifically among sex offenders.
However, some authors have noted that the difficulty in determining a clear prevalence of sexual addiction may be related to the still poorly defined diagnostic criteria for this disorder as well as the choice of measurement tools.
In the inmate population, to our knowledge, there are no French prevalence studies of this disorder. In addition, no studies have been conducted to compare the prevalence of sexual addiction among sex offenders (SASO) with that among non-sex offenders (SANSO).
We hope that better screening for addiction would enable better management of patients with this disorder, promoting their psychosocial rehabilitation and well-being, so as to prevent the recurrence of a transition to sexual arousal.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Julien JD Da Costa, MD
- Phone Number: +33 05 61 14 90 10
- Email: julien.da-costa@ch-marchant.fr
Study Locations
-
-
-
Toulouse, France, 31000
- Julien DA COSTA
-
Contact:
- Julien JD Da Costa, MD
- Phone Number: +33 05 61 14 90 10
- Email: julien.da-costa@ch-marchant.fr
-
Principal Investigator:
- Julien JD Da Costa, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male subjects
- Detainees at Muret Detention Center
- Aged between 18 and 65 at the time of the search
- And having agreed to participate in the research.
Exclusion Criteria:
- Person under legal protection, guardianship or curatorship ;
- Insufficient command of the French language
- Existence of cognitive disorders preventing a good understanding of the information relating to the study or the various questionnaires.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Interviews
semi-directive interview
|
semi-structured interview conducted by a psychiatrist
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The main objective is to determine the prevalence of sexual addiction among a population of men incarcerated at the Muret detention center in Haute-Garonne.
Time Frame: Day 1
|
The primary endpoint is the presence of a patient's sexual addiction defined by a score greater than 13 on the Carnes screening test.
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine the prevalence of sexual addiction in a population of sexual offenders
Time Frame: Day 1
|
The distribution of the proportions of people with sexual addiction is defined by a score greater than 13 on the Carnes screening test in two population groups, perpetrators of sexual offenses and perpetrators of non-sexual offenses.
|
Day 1
|
Determine the prevalence of sexual addiction in a population of non-sexual offenders
Time Frame: Day 1
|
The distribution of the proportions of people with sexual addiction is defined by a score greater than 13 on the Carnes screening test in two population groups, perpetrators of sexual offenses and perpetrators of non-sexual offenses.
|
Day 1
|
Compare the prevalence of sexual addiction in these two populations
Time Frame: Day 1
|
The distribution of the proportions of people with sexual addiction is defined by a score greater than 13 on the Carnes screening test in two population groups, perpetrators of sexual offenses and perpetrators of non-sexual offenses.
|
Day 1
|
Determine any addictive and psychiatric co-morbidities associated with each population
Time Frame: Day 1
|
The presence of psychiatric disorders is defined using the Mini International Neuropsychiatric Interview (MINI) scale.
|
Day 1
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-A00342-41
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sexual Addiction
-
American Foundation for Addiction ResearchUniversity of Alberta; University of Southern MississippiUnknownSexual AddictionUnited States
-
Centre Hospitalier St AnneNot yet recruitingSexual Addiction | Hypersexualism
-
The Hong Kong Polytechnic UniversityRecruiting
-
City University of Hong KongCompletedQuality of Life | Psychological Distress | Internet Gaming Disorder | Social Media Addiction | Smartphone AddictionChina
-
Gazi UniversityRecruitingAddiction | Physical Inactivity | Social Media AddictionTurkey
-
Daegu Catholic University Medical CenterCompletedInternet AddictionKorea, Republic of
-
The Hong Kong Polytechnic UniversityRecruitingPrevalence of Internet Addiction and it's Effects on Psychological Well-being of Adults in Hong KongInternet AddictionHong Kong
-
Dr. Wang Man-PingActive, not recruiting
-
Mustafa YumusakCumhuriyet UniversityNot yet recruitingSmartphone Addiction | Students, NursingTurkey
-
Kutahya Health Sciences UniversityCompletedMental Fatigue | Smartphone AddictionTurkey
Clinical Trials on semi-structured Interviews
-
Indiana UniversityPatient-Centered Outcomes Research InstituteRecruitingColorectal Cancer ScreeningUnited States
-
Institut Paoli-CalmettesNot yet recruiting
-
Region SkaneLund UniversityCompletedSuicidal Ideation | Self-Harm, Deliberate | Self Injurious Behavior Without Suicidal IntentSweden
-
University of New MexicoSociety of Family PlanningWithdrawnPregnancy TerminationUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedChronic (Non-malignant) Musculoskeletal PainFrance
-
Fundació Institut de Recerca de l'Hospital de la...UnknownChemotherapy-induced AlopeciaSpain
-
University of NimesNot yet recruitingCancer Colorectal | Hypnosis, AnimalFrance
-
The Royal Orthopaedic Hospital NHS TrustCompletedGreater Trochanteric Pain SyndromeUnited Kingdom
-
Hospices Civils de LyonCompletedStroke | Breast Cancer | AsthmaFrance
-
Memorial Sloan Kettering Cancer CenterCompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal CancerUnited States